Experimental antitumor activity of BMY-28090, a new antitumor antibiotic

@article{Schurig2004ExperimentalAA,
  title={Experimental antitumor activity of BMY-28090, a new antitumor antibiotic},
  author={John E. Schurig and William T. Bradner and George A. Basler and William C. Rose},
  journal={Investigational New Drugs},
  year={2004},
  volume={7},
  pages={173-178}
}
SummaryBMY-28090 is a novel actinomycete fermentation derived antitumor agent. The cytotoxic effect of BMY-28090 was evaluated in two murine and eight human tumor cell lines in vitro. Following 72-hour exposures, BMY-28090 was cytotoxic for all of these cell lines with IC50 values of < 0.02 to 3.25 μg/ml. BMY-28090 was evaluated for in vivo antitumor activity in a variety of experimental murine tumor and human tumor xenograft models. Initial testing against the murine tumor models was performed… 
Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration
TLDR
IT-622 showed an in vivo antitumor effect superior to that of authentic A-132, possibly resulting from a higher absorption ratio of IST- 622 through the gastrointestinal tract, and is under clinical phase I study in Japan.
An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
TLDR
The MTD and recommended dose for Phase II trials of elsamitrucin is 0.08 mg/kg i.v. weekly, and this drug might be considered for combination protocols with myelosuppressive chemotherapy agents.
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
TLDR
The activity of elsamitrucin in this group of patients and its lack of myelosuppression suggest utility in this disease especially when combined with other proven agents.
Emerging DNA topoisomerase inhibitors as anticancer drugs
TLDR
This review covers 24 drugs that inhibit or poison the function of topoisomerase (topo) enzymes at various stages of clinical development, and finds that many of the latter class are at an early stage of development, despite a lack of detailed structural biology on the target enzymes.
Emerging DNA topisomerase inhibitors as anticancer drugs.
  • W. Denny
  • Biology, Chemistry
    Expert opinion on emerging drugs
  • 2004
TLDR
This review covers 24 drugs that inhibit or poison the function of topoisomerase (topo) enzymes at various stages of clinical development, and finds that many of the latter class are at an early stage of development, despite a lack of detailed structural biology on the target enzymes.

References

SHOWING 1-10 OF 10 REFERENCES
Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
TLDR
Because of its antitumor activity, novel structure, high potency (effective at µg/kg dose levels), strong binding affinity to DNA, and apparent lack of certain organ toxicities, further development of this compound or its analogs is being considered.
A microtitre cytotoxicity assay useful for the discovery of fermentation-derived antitumor agents
TLDR
A microtiter cytoxicity assay using mammalian cell lines was developed to detect fermentation-derived antitumor agents and the cytotoxicity assay predictive rate was twice that of the antimicrobial assays.
Evaluation of platinol analogs using the M5076 murine sarcoma.
  • W. Rose
  • Chemistry
    Anticancer research
  • 1986
TLDR
The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol, carboplatin, and iproplatin and the essential clinical inactivity of spiroplatin thus far reported.
Evaluation of platinol analogs using the M5076 murine sarcoma.
TLDR
The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol, carboplatin, and iproplatin and the essential clinical inactivity of spiroplatin thus far reported.
Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
TLDR
New antitumor antibiotics, elsamicin A and B, were isolated from the culture broth of an unidentified actinomycete strain J907-21 (ATCC 39417) and were found to be 10-30 times more potent than that of chartreusin in terms of minimum effective dose.
Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo
TLDR
A microtiter assay was developed to monitor cytotoxic activity of drugs alone and in combination at varying ratios on a single plate and indicated that metoclopramide did not interfere with cisplatin-induced cytotoxicity and confirmed previously reported inhibition of cisPlatin activity by sodium thiosulfate.
Über die Struktur des Chartreusins I
1 Die Experimente, die zur Aufstellung der Strukturformel IV fur das Aglykon aus dem Antibiotikum Chartreusin gefuhrt haben, werden beschrieben. 2 STERNBACH, KAISER & GOLDBERG [2] haben
BMY-28090 a new antitumor antibiotic related to chartreusin: Isolation, chemistry and activity
  • Abs 14th Int Congr Chemother:320,
  • 1985
Growth and treatment of a human colon tumor cell line xenografted in the subrenal capsule (src) of irradiated mice
  • (Abstr) Proc Amer Assoc Cancer Res
  • 1986